curetis产品代理
curetis产品代理
Curetis GmbH 位于德国高科技产业的中心地带斯图加特附近，现在是 OpGen 集团的一家公司。 Curetis GmbH 开发和商业化分子诊断产品已超过 10 年，旨在应对检测严重传染病和识别住院患者抗生素耐药性的全球挑战。
2018 年， Curetis 获得了美国第一个下呼吸道多重 PCR 诊断面板的 FDA 批准 - 用于气管抽吸样品的 Unyvero LRT 面板，随后在 2019 年获得 FDA 批准用于支气管肺泡灌洗样品的 Unyvero LRT BAL。有了 Unyvero LRT 和 LRT BAL，医院可以在症状检测的帮助下更快地诊断严重的肺炎感染并针对有效的抗生素治疗进行靶向治疗。更快、更有针对性的治疗可以降低死亡率、降低医疗保健成本并更好地利用现有抗生素。
2020 年，Curetis 将其业务与 OpGen 相结合，为严重感染构建更强大的诊断解决方案。在美国，Unyvero 产品由 OpGen, Inc. 独家经销。
我们的 OpGen 集团公司 Ares Genetics GmbH 为传染病诊断和治疗提供下一代解决方案，这些解决方案基于下一代测序 (NGS) 与人工智能驱动的数据分析相结合。在 Ares Genetics，我们的愿景是提供一种通用解决方案，在任何患者样本中都可以识别任何病原体并准确预测其对抗感染药物治疗的敏感性。 ARES 技术平台将我们认为是世界上最全面的抗菌素耐药性遗传学数据库 ARESdb 与先进的生物信息学和人工智能解决方案相结合。通过与 AcuitasLighthouse 平台的集成，它将在深度和范围上进一步增强。
The powerful Unyvero technology was originated in Germany, and Unyvero products are manufactured by Curetis GmbH. In the USA, Unyvero products are exclusively distributed by OpGen, Inc.
Curetis GmbH is located near Stuttgart in the heartland of German high-tech industry, and it is now an OpGen Group company. Curetis GmbH has been developing and commercializing molecular diagnostic products for more than 10 years, designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients.
In 2018, Curetis received FDA clearance for America’s first Lower Respiratory multiplex PCR diagnostic panel -the Unyvero LRT Panel for tracheal aspirate samples, followed by FDA clearance of the Unyvero LRT BAL for bronchoalveolar lavage samples in 2019. With theUnyvero LRT and LRT BAL, hospitals can diagnose serious Pneumonia infections and target effective antibiotic treatment with the help of syndromic testing faster. Faster, targeted treatment leads to reduced mortality, reduced healthcare costs and better utility of available antibiotics.
In 2020, Curetis combined its business with OpGen to build
stronger diagnostic solutions for severe infections. In the USA,Unyvero products are exclusively distributed by OpGen, Inc.
Our OpGen Group company Ares Genetics GmbH offers next-generation solutions for infectious disease diagnostics and therapeutics thatare based on the combination of Next Generation Sequencing (NGS) with artificial intelligence powered data analytics. At Ares Genetics we have the vision to provide a universal solution that in any patient sample can identify any pathogen and accurately predict its susceptibility to anti-infective drug therapy. The ARES Technology Platform combines what we believe is the world’s most comprehensive databases on the genetics of antimicrobial resistances, ARESdb, with advanced bioinformatics and artificial intelligence solutions. It will be further enhanced in depth and scope through its integration with the AcuitasLighthouse Platform.
